Biocryst Pharmaceuticals reported $-58859000 in Net Income for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
DBV Technologies DBVT:US -23039000 6.33M
Alnylam Pharmaceuticals ALNY:US $ -277.4M 37.06M
Biocryst Pharmaceuticals BCRX:US $ -58.86M 15.34M
Chugai Pharma 4519:JP Y 72378M 59397M
Daiichi Sankyo 4568:JP Y 18852M 46197M
Enanta Pharmaceuticals ENTA:US $ -31.7M 1.89M
Gilead Sciences GILD:US $ 1144M 1125M
Glaxosmithkline GSK:US $ 838M 964M
GlaxoSmithKline GSK:LN 838M 964M
Intra Cellular Therapies ITCI:US $ -86.6M 14.48M
IONIS PHARMACEUT IONS:US $ -105.14M 39.97M
Karyopharm Therapeutics KPTI:US $ -49062000 7.66M
Mirati Therapeutics MRTX:US $ -176.44M 11.94M
Neurocrine Biosciences NBIX:US $ -16.9M 30.8M
Ptc Therapeutics PTCT:US $ -152.09M 25.36M
Regeneron Pharmaceuticals REGN:US $ 852.1M 121.4M
Sarepta Therapeutics SRPT:US $ -231.48M 126.46M
Ultragenyx Pharmaceutical RARE:US $ -158.16M 5.84M
Vertex Pharmaceuticals VRTX:US $ 810.5M 48.4M
YTE INCY:US $ 161.43M 123.44M